Table 2 All adverse events observed during the study period
All adverse events—no. (%) | Grade I | Grade II | Grade III |
|---|---|---|---|
Atrial fibrillation | 1 (1.6%) | 1 (1.6%) | 0 (0%) |
Sinus bradycardia | 2 (3.2%) | 0 (0%) | 0 (0%) |
Sinus tachycardia | 3 (4.8%) | 0 (0%) | 0 (0%) |
Blurred vision | 1 (1.6%) | 0 (0%) | 0 (0%) |
Fatigue | 2 (3.2%) | 3 (4.8%) | 0 (0%) |
Fever | 3 (4.8%) | 0 (0%) | 0 (0%) |
Pneumonia | 0 (0%) | 0 (0%) | 1 (1.6%) |
Urinary tract infection | 0 (0%) | 0 (0%) | 1 (1.6%) |
Lymphocyte count decreased | 2 (3.2%) | 1 (1.6%) | 0 (0%) |
Neutrophil count decreased | 1 (1.6%) | 2 (3.2%) | 0 (0%) |
Platelet count decreased | 1 (1.6%) | 0 (0%) | 0 (0%) |
Anorexia | 2 (3.2%) | 2 (3.2%) | 0 (0%) |
Hypercalcemia | 1 (1.6%) | 0 (0%) | 0 (0%) |
Vomiting | 3 (4.8%) | 0 (0%) | 0 (0%) |
Nausea | 4 (6.5%) | 0 (0%) | 0 (0%) |
Dizziness | 1 (1.6%) | 1 (1.6%) | 0 (0%) |
Hypotension | 2 (3.2%) | 1 (1.6%) | 0 (0%) |
Headache | 2 (3.2%) | 2 (3.2%) | 0 (0%) |
Lethargy | 3 (4.8%) | 1 (1.6%) | 0 (0%) |
Seizure | 0 (0%) | 2 (3.2%) | 0 (0%) |
Dyspnea | 1 (1.6%) | 0 (0%) | 0 (0%) |
Thromboembolic event | 1 (1.6%) | 2 (3.2%) | 0 (0%) |
Diarrhea | 1 (1.6%) | 0 (0%) | 0 (0%) |
Hyperglycemia | 2 (3.2%) | 1 (1.6%) | 0 (0%) |
Intervention-related adverse events—no. (%) | |||
 Wound dehiscence | 1 (1.6%) | 0 (0%) | 0 (0%) |
 Wound infection | 0 (0%) | 1 (1.6%) | 0 (0%) |